Real-World Evidence Conference
Session 3: How Does the Growing Use of RWE to Support Regulatory Decision-Making Impact Generation of Post-Marketing RWE?
Session Chair(s)
Marni Hall, PhD, MPH
- Vice President, Clinical Evidence
- IQVIA, United States
Delphine Saragoussi, MD, MSc
- Executive Director, Real-World Evidence
- Evidera, France
The focus of RWE generation in the regulatory space has recently expanded from the post-marketing phase to the pre-marketing phase with increasing focus on generating RWE to support regulatory decision-making. This has been driven first by the need to optimize data generation in rare diseases and precision medicine, has been boosted by the COVID-19 pandemic and an unprecedented wave of emergency use authorizations; it is also used as a way to ensure more diversity in clinical research.
By putting RWE under the spotlight and by creating a continuum of RWE between the pre- and post-marketing space, this recent development is expected to impact the way post-marketing RWE is generated, e.g. in terms of scope, methods and data quality
Experts from the pharmaceutical industry will share their experience and perspective on these changes globally and how they impact the way they generate post-marketing RWE on a daily basis and will have the opportunity to exchange with a regulator. In particular, they will focus on the early planning of post-marketing RWE, the choice of data sources, and data quality requirements. They will also share practical learnings on engaging with regulators on RWE.
Learning Objective : At the conclusion of this session, participants should be able to:
- Discuss the most current trends for the use of real- world evidence and data
- Describe some scenarios where post-marketing RWE generation is influenced by current trends in the pre-marketing space
- Identify opportunities and challenges of RWE generation in the regulatory context
Speaker(s)
Speaker
Richard Forshee, PhD
- Deputy Director, OBPV CBER
- FDA, United States
Speaker
Alison Cave, PhD
- Chief Safety Officer
- Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
Speaker
Patrice Verpillat, DrMed, MD, PhD, MPH
- Head of Global Epidemiology
- Merck Healthcare KGaA, Germany
Speaker
Rohini Hernandez, PhD, MPH
- Director, Center for Observational Research
- Amgen, United States
Contact us
Registration Questions?
Preconference Short Courses
Additional Information
Sign up to be notified when registration opens for the DIA 2022 Events
Real-World Evidence Conference Resource Kit